Drotaverine Hydrochloride is a defined ionic salt form offering distinct advantages in pharmaceutical processing and performance over the free acid or base. The counter-ion in Drotaverine Hydrochloride has been selected based on toxicological acceptability at daily intake levels achievable from the proposed dosage regimen, and compatibility with the drug product excipient matrix. Solid-state characterisation of Drotaverine Hydrochloride includes polymorph screening, stability under accelerated conditions, and determination of hygroscopic behaviour that may affect powder processing, fill weight uniformity, and long-term chemical stability in the drug product.
Interspecies uncertainty factor F1 refinement for Drotaverine Hydrochloride is achievable when comparative toxicokinetic data characterise the AUC ratio between humans and the test species at relevant doses, replacing the default allometric scaling assumption.
